# Pharma-Bio Serv, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Pharma-Bio Serv, Inc.). ## Overview Pharma-Bio Serv, Inc. is a Puerto Rico-based technical compliance consulting firm organized in Delaware and serving clients in the United States, Puerto Rico, Europe and, to a lesser extent, Brazil. It provides regulatory affairs, quality, validation, technology transfer, engineering, project management and process support services to regulated life-science and allied industries. ## Products & services • Regulatory affairs and FDA compliance consulting • Validation and qualification services • Technology transfer support • Quality and process support services • Engineering and project management consulting - **Regulatory compliance consulting** (35%) — Advisory services that help clients meet FDA and international regulatory requirements. - **Validation and qualification services** (25%) — Testing, documentation and qualification work for regulated facilities, systems and processes. - **Technology transfer services** (15%) — Support for transferring products, processes and methods between sites or organizations. - **Engineering and project management** (15%) — Technical project execution, process support and implementation services for client operations. - **Quality and process support** (10%) — Ongoing quality assurance, compliance remediation and operational support services. - Regulatory affairs and FDA compliance consulting - Validation and qualification services - Technology transfer support - Quality and process support services - Engineering and project management consulting ## Customers The company serves pharmaceutical, biotechnology, medical device, chemical, cosmetic and food manufacturers, plus allied products companies. Its work is typically project-based and tied to regulatory, validation and technology-transfer needs at client facilities, which makes large regulated manufacturers the core customer base. A small number of customers can represent a meaningful share of annual revenue, reflecting the concentration common in specialized consulting engagements. - **Pharmaceutical manufacturers** (primary) — Buy regulatory, validation and technology-transfer services to support manufacturing and compliance. - **Biotechnology companies** (primary) — Buy quality, process and regulatory support for development and production environments. - **Medical device companies** (primary) — Buy validation, qualification and compliance consulting for regulated operations. - **Chemical manufacturers** (secondary) — Buy technical compliance and process support for regulated production activities. - **Cosmetics, food and allied products companies** (secondary) — Buy compliance and technical support where product and facility regulations apply. - Large pharmaceutical manufacturers needing FDA and global compliance support - Biotechnology companies requiring validation and technology transfer work - Medical device makers with regulated quality and qualification needs - Chemical and allied-products companies facing process and compliance requirements - Food and cosmetic manufacturers needing technical compliance support ## Geography Pharma-Bio Serv is headquartered in Puerto Rico and operates across Puerto Rico, the United States and Europe, with a smaller and developing presence in Brazil. In the latest disclosed quarterly regional mix, Puerto Rico and the United States remained the largest revenue contributors, while Europe represented a meaningful and variable share depending on project timing. Geography matters because the company’s work is tied to local regulated manufacturing activity, client capital spending and cross-border compliance requirements. - **Puerto Rico** (50.7%) — Nine months ended July 31, 2025 revenue mix - **United States** (29.2%) — Nine months ended July 31, 2025 revenue mix - **Europe** (19.8%) — Nine months ended July 31, 2025 revenue mix - **Other** (0.3%) — Nine months ended July 31, 2025 revenue mix - Headquartered in Puerto Rico, which is a core operating base - Puerto Rico is a major revenue market and client concentration area - The United States is another primary market for compliance consulting - Europe is an important growth and project market for the company - Brazil is a smaller, developing market with limited current presence ## Strategy The company’s strategy is to deepen relationships with large regulated manufacturers by delivering specialized compliance and technology-transfer services. It also seeks to broaden its market presence in the United States, Europe and Brazil while recruiting and retaining highly experienced technical consultants. Because the business is project-based, winning repeat work and expanding account penetration are central to sustaining its competitive position. - **Expand geographic reach** (medium-term) — Broader market coverage reduces dependence on any one region and opens more client opportunities. - **Strengthen technical talent base** (short-term) — The business depends on specialized consultants with regulated-industry expertise. - **Increase account penetration** (short-term) — Larger existing customers can generate recurring project opportunities and higher utilization. - Expand compliance services across regulated life-science markets - Grow presence in the United States, Europe and Brazil - Win larger accounts and repeat project work - Recruit and retain experienced engineering and life-science consultants - Use trade shows, seminars and direct account marketing to generate leads ## Risks The business is exposed to customer concentration, since a small number of clients can account for a large share of revenue in a given year. It also depends on regulated industries and regional manufacturing activity, so changes in FDA or international rules, client capital spending, inflation, tax policy or economic conditions can reduce demand for consulting services. Competition is fragmented and entry barriers are modest, which can pressure pricing and make talent retention important. - **Customer concentration** [high] — Three customers represented 43.5% of revenue in fiscal 2025, so losing a major account would materially affect results. - **Regulatory change risk** [high] — The company sells services that are driven by FDA and international compliance requirements. - **Competitive pressure** [medium] — The market includes local, national and international consulting firms, some with greater resources. - **Macroeconomic and industry cyclicality** [medium] — Client spending on compliance projects can slow when inflation, interest rates or industry consolidation affect investment decisions. - Customer concentration can cause revenue volatility if a major client is lost - Demand depends on regulated manufacturing activity and client project budgets - Regulatory changes can alter the need for compliance and validation services - Competition is fragmented and includes larger firms with more resources - Talent retention is critical because services depend on specialized consultants ## Accounting Revenue is project-based, so timing can vary with contract completion, client schedules and regional project mix. Investors should also watch the allowance for credit losses on receivables, because collections depend on a concentrated base of large customers, and foreign exchange effects on intercompany balances can affect other income. Lease accounting, income tax estimates and any stock repurchase activity are additional areas where judgment can affect reported results and balance-sheet presentation. - **Project revenue timing** — Affects revenue comparability across periods - **Allowance for credit losses** — Affects bad debt expense and net receivables - **Foreign exchange on intercompany balances** — Affects other income, net - **Income taxes and valuation allowance** — Affects tax expense and deferred tax balances - **Leases** — Affects leverage and operating expense presentation - Project-based revenue can shift quarter to quarter with contract timing - Allowance for credit losses depends on customer quality and collectability - Foreign exchange on intercompany balances can affect other income - Lease accounting affects balance sheet liabilities and expense recognition - Income tax estimates and valuation allowances depend on future realizability --- *Last updated: 2026-04-29T04:48:33.118068+00:00*